机构:[1]Nephrology,School of Traditional Medicine, Guangzhou University of Chinese Medicine,Guangzhou, Guangdong, 510006, China[2]Internal Medicine,The Integrated Division of Chinese and Western Medicine, Guangdong General Hospital, Guangdong Academy of Geriatrics,Guangzhou, Guangdong, 510080, China广东省人民医院[3]Geriatrics,The Integrated Division of Chinese and Western Medicine, Guangdong General Hospital, Guangdong Academy of Geriatrics,Guangzhou, Guangdong, 510080, China广东省人民医院[4]Geriatrics, Nephrology,The Integrated Division of Chinese and Western Medicine, Guangdong General Hospital, Guangdong Academy of Geriatrics,Guangzhou, Guangdong, 510080, China广东省人民医院
出处:
ISSN:
摘要:
Diabetic nephropathy (DN) is the most frequent cause of end-stage renal disease. The activation of the renin-angiotensin system (RAS) and lipid disorders are major risk factors in progressive chronic kidney disease. Inhibition of the RAS is one of the most widely used therapies to treat chronic kidney disease. But its effect is not sufficient, and lowered hyperlipidemia is required. Most of medications for hypertension have effects only on the blood pressure in DN. This study is to evaluate the influence of irbesartan on blood lipid, kidney function, and the pathological change of kidney, liver, and adipose tissue.
Six-week old db/db mice were randomly assigned to control group and irbesartan group. Mice in irbesartan group were fed 40 mg/kg irbesartan each day. Eight weeks later, blood lipid, kidney function, and the pathological change of kidney, liver, and adipose tissue were measured.
The results indicated that the blood lipid, uric acid, urea nitrogen, and creatinine of db/db mice increased significantly. There are obvious vacuolar degeneration and ballooned hepatocytes around the central vein of db/db mouse liver. Kidney biopsy found glomerular hypertrophy of glomerular, mesangial thickening, and vacuolar degeneration. Irbesartan can decrease the blood pressure, blood lipid, and kidney lipid. But it has no effects on blood glucose and liver lipid. It can improve the function and pathological change of kidney of db/db mice. But it has no effects on pathological change of adipose tissue and liver.
Irbesartan can decrease blood lipid and protect the kidney of db/db mice, and is a good choice of treatment for diabetic nephropathy.
基金:
This work is supported by the Foundation of Guangdong Provincial Natural Science (S2012010010783).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[-1]版:
无
最新[2025]版:
大类|4 区医学
小类|4 区医学:研究与实验
第一作者:
第一作者机构:[1]Nephrology,School of Traditional Medicine, Guangzhou University of Chinese Medicine,Guangzhou, Guangdong, 510006, China
通讯作者:
通讯机构:[2]Internal Medicine,The Integrated Division of Chinese and Western Medicine, Guangdong General Hospital, Guangdong Academy of Geriatrics,Guangzhou, Guangdong, 510080, China[*1]The Integrated Division of Chinese and Western Medicine, Guangdong General Hospital, Guangdong Academy of Geriatrics, Guangzhou, Guangdong 510080, China.
推荐引用方式(GB/T 7714):
Chunyi Wang,Cunyun Min,Xianglu Rong,et al.Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy.[J].Discovery medicine.20(108):67-77.
APA:
Chunyi Wang,Cunyun Min,Xianglu Rong,Tingting Fu,Xuhui Huang&Changjun Wang.(0).Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy..Discovery medicine,20,(108)
MLA:
Chunyi Wang,et al."Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy.".Discovery medicine 20..108(0):67-77